MarketPulse

relacorilant

57 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Misleading FDA Claims

Schall Law Firm seeks investors in $COPT securities class action, alleging false statements about relacorilant FDA approval prospects between October 2024 and December 2025.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

$CORT Faces Securities Lawsuit Over Relacorilant Approval Claims

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Hit With Securities Fraud Class Action Over Relacorilant Claims

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

CORT Plunges 50% After FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

CORT Stock Crashes 50% on FDA Rejection; Class Action Lawsuit Deadline Looms

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Stock Crashes 50% After FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Corcept Therapeutics Hit with Class Action Over FDA Drug Study Misrepresentations

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Corcept Therapeutics

Rosen Law Firm sues Corcept Therapeutics for allegedly making misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug candidate.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Faces Securities Lawsuit Over Relacorilant Claims as FDA Rejection Triggers 50% Stock Decline

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Corcept Misrepresented Relacorilant Clinical Data

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Portnoy Law Firm Files Class Action Against Corcept Therapeutics Over FDA Drug Rejection

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Corcept Investors Face April Deadline in Securities Litigation Over FDA Rejection

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Faces Securities Lawsuit Over Relacorilant FDA Rejection

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed FDA Setback

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Law Firm Initiates Class Action Against Corcept Therapeutics Over Relacorilant Claims

Law firm Bernstein Liebhard files class action lawsuit against Corcept Therapeutics for alleged material misrepresentations about relacorilant drug clinical evidence.
SMRCORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Corcept Therapeutics Faces Class Action Over Relacorilant FDA Rejection

Corcept Therapeutics faces class action lawsuit over alleged misrepresentation regarding relacorilant drug. FDA rejected the application citing insufficient efficacy data; stock plummeted over 50%.
CORTsecurities fraudclass action lawsuit